- Home
- LEGN vs CZR Comparison
LEGN vs CZR Comparison
Compare LEGN & CZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGN
- CZR
- Stock Information
- Founded
- LEGN 2014
- CZR 1937
- Country
- LEGN United States
- CZR United States
- Employees
- LEGN N/A
- CZR N/A
- Industry
- LEGN Biotechnology: Pharmaceutical Preparations
- CZR Hotels/Resorts
- Sector
- LEGN Health Care
- CZR Consumer Discretionary
- Exchange
- LEGN Nasdaq
- CZR Nasdaq
- Market Cap
- LEGN 7.0B
- CZR 7.3B
- IPO Year
- LEGN 2020
- CZR 1989
- Fundamental
- Price
- LEGN $33.65
- CZR $24.81
- Analyst Decision
- LEGN Strong Buy
- CZR Strong Buy
- Analyst Count
- LEGN 13
- CZR 14
- Target Price
- LEGN $79.17
- CZR $48.79
- AVG Volume (30 Days)
- LEGN 1.1M
- CZR 6.1M
- Earning Date
- LEGN 03-11-2025
- CZR 04-29-2025
- Dividend Yield
- LEGN N/A
- CZR N/A
- EPS Growth
- LEGN N/A
- CZR N/A
- EPS
- LEGN N/A
- CZR N/A
- Revenue
- LEGN $627,241,000.00
- CZR $11,245,000,000.00
- Revenue This Year
- LEGN $66.60
- CZR $4.60
- Revenue Next Year
- LEGN $49.28
- CZR $2.55
- P/E Ratio
- LEGN N/A
- CZR N/A
- Revenue Growth
- LEGN 119.97
- CZR N/A
- 52 Week Low
- LEGN $30.17
- CZR $25.43
- 52 Week High
- LEGN $60.87
- CZR $45.93
- Technical
- Relative Strength Index (RSI)
- LEGN 44.07
- CZR 26.33
- Support Level
- LEGN $34.00
- CZR $26.73
- Resistance Level
- LEGN $36.20
- CZR $28.45
- Average True Range (ATR)
- LEGN 1.52
- CZR 1.14
- MACD
- LEGN -0.25
- CZR -0.09
- Stochastic Oscillator
- LEGN 25.18
- CZR 3.05
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
About CZR Caesars Entertainment Inc.
Caesars Entertainment includes about 50 domestic gaming properties across Las Vegas (49% of 2023 EBITDAR before corporate expenses) and regional (48%) markets. Additionally, the company hosts managed properties and digital assets, the later of which produced marginal EBITDA in 2023. Caesars' US presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973 and expanded its presence through prior acquisitions to over 20 properties before merging with legacy Caesars. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the US portion of William Hill (it sold the international operation in 2022), a digital sports betting platform.